Nuwellis Advances Financial Efficiency Strategy with Improved Gross Margins

MINNEAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, highlights continued progress under its financial efficiency strategy, including significant gross margin improvement, sustained product quality and supply performance, and further optimization of its cost structure. This strategy continues to advance alongside a strengthened cash position, extending the Company’s operating runway into the third quarter of 2027.

"Over the past year, we have made meaningful progress building a more efficient and scalable operating model while continuing to grow revenues at a double-digit rate," said Mike McCormick, Nuwellis President and Chief Executive Officer. "Our transition to outsourced manufacturing has reduced our cost structure while maintaining the product quality and supply performance our customers expect. We are seeing tangible results from these initiatives and remain focused on our goal of consistently reducing our monthly cash burn.”

September marks the first anniversary of Nuwellis' transition of Aquadex production to KDI Manufacturing, its contract manufacturer. Nuwellis’ former manufacturing employees were successfully incorporated into KDI's operations, supporting continuity in production and supply while also reducing costs. Since that time, KDI Manufacturing has delivered nearly 5,000 AquaFlexFlow^® blood circuits and 30 Aquadex SmartFlow^® consoles to Nuwellis, as well as servicing more than 200 consoles. Throughout the transition, finished goods have continued to pass quality inspections at rates comparable to those achieved before the transition.

The transition to contract manufacturing, combined with ongoing operational discipline, is yielding measurable improvements in Nuwellis’ financial profile. Gross margin increased to 76% for the second quarter of 2026, compared with 56% for the same period in the prior year.

As of August 31, 2026, Nuwellis had approximately $8.8 million in cash, which the Company estimates will provide runway into the third quarter of 2027 based on its current operating plan. This strengthened cash position, coupled with its cost-containment efforts, is expected to provide the Company the flexibility to invest in key growth initiatives to advance its financial objectives.

“Strengthening the balance sheet is only part of the equation, protecting it is equally important,” said Nuwellis Chief Financial Officer Carisa Schultz. “We will continue to manage expenses carefully and maintain a high bar for new investment. Our goal is to direct capital toward the near-term product development and market opportunities we believe can create the greatest value while maintaining the financial discipline we have worked hard to establish.”

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis' strategy includes expanding its portfolio through internally developed technologies and strategic commercial partnerships that broaden its presence across acute and chronic critical care. For more information, visit www.nuwellis.com.

Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.

For further information, please contact:

Investor Relations:
CORE IR
ir@nuwellis.com

Media Contact:
CORE PR
media@nuwellis.com